[{"orgOrder":0,"company":"Chiesi Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ITALY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Beclomethasone Dipropionate","moa":"||Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Chiesi Group","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Chiesi Group \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chiesi Group \/ Inapplicable"},{"orgOrder":0,"company":"Chiesi Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ITALY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Beclomethasone Dipropionate","moa":"||Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Chiesi Group","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Chiesi Group \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chiesi Group \/ Inapplicable"},{"orgOrder":0,"company":"Chiesi Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ITALY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Beclomethasone Dipropionate","moa":"||Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase III","graph3":"Chiesi Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Inhalation","sponsorNew":"Chiesi Group \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Chiesi Group \/ Inapplicable"},{"orgOrder":0,"company":"Chiesi Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ITALY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Beclomethasone Dipropionate","moa":"||Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Chiesi Group","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Pressurised Metered Dose Inhaler","sponsorNew":"Chiesi Group \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chiesi Group \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"INDIA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Formoterol Fumarate","moa":"||ADRB2","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Nasal Pressurised Metered Dose Inhaler","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"},{"orgOrder":0,"company":"Chiesi Group","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ITALY","productType":"Other Small Molecule","year":"2020","type":"Collaboration","leadProduct":"Beclomethasone Dipropionate","moa":"||Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Chiesi Group","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Pressurised Metered Dose Inhaler","sponsorNew":"Chiesi Group \/ Bayer AG","highestDevelopmentStatusID":"15","companyTruncated":"Chiesi Group \/ Bayer AG"},{"orgOrder":0,"company":"Chiesi Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ITALY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Beclomethasone Dipropionate","moa":"||Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Chiesi Group","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral Pressurised Metered Dose Inhaler","sponsorNew":"Chiesi Group \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chiesi Group \/ Inapplicable"},{"orgOrder":0,"company":"Chiesi Group","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"ITALY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Beclomethasone Dipropionate","moa":"||Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Approved FDF","graph3":"Chiesi Group","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Metered Dose Inhaler","sponsorNew":"Chiesi Group \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Chiesi Group \/ Inapplicable"},{"orgOrder":0,"company":"DARTNet Institute","sponsor":"Penn State University | Icahn School of Medicine at Mount Sinai | University of Colorado, Denver | RAND Corporation | University of Washington | Rutgers University | University of North Carolina | Brigham and Women's Hospital | Reliant Medical Group | Kel","pharmaFlowCategory":"DU","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Beclomethasone Dipropionate","moa":"||Glucocorticoid receptor","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase IV","graph3":"DARTNet Institute","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DARTNet Institute \/ Penn State University | Icahn School of Medicine at Mount Sinai | University of Colorado, Denver | RAND Corporation | University of Washington | Rutgers University | University of North Carolina | Brigham and Women's Hospital | Reliant Medical Group | Kel","highestDevelopmentStatusID":"11","companyTruncated":"DARTNet Institute \/ Penn State University | Icahn School of Medicine at Mount Sinai | University of Colorado, Denver | RAND Corporation | University of Washington | Rutgers University | University of North Carolina | Brigham and Women's Hospital | Reliant Medical Group | Kel"},{"orgOrder":0,"company":"Lipidor AB","sponsor":"Menarini","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"SWEDEN","productType":"Other Small Molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Calcipotriol","moa":"||Vitamin D receptor","graph1":"Dermatology","graph2":"Phase III","graph3":"Lipidor AB","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Topical Spray","sponsorNew":"Lipidor AB \/ Menarini","highestDevelopmentStatusID":"10","companyTruncated":"Lipidor AB \/ Menarini"},{"orgOrder":0,"company":"UPECLIN HC FM Botucatu Unesp","sponsor":"Chiesi Group","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Beclomethasone Dipropionate","moa":"||Glucocorticoid receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"UPECLIN HC FM Botucatu Unesp","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UPECLIN HC FM Botucatu Unesp \/ Chiesi Group","highestDevelopmentStatusID":"8","companyTruncated":"UPECLIN HC FM Botucatu Unesp \/ Chiesi Group"},{"orgOrder":0,"company":"Humanis","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"TURKEY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Azelastine Hydrochloride","moa":"||Histamine H1 receptor","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Humanis","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Humanis \/ Inapplicable","highestDevelopmentStatusID":"7","companyTruncated":"Humanis \/ Inapplicable"},{"orgOrder":0,"company":"Sofar Spa","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"ITALY","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Beclomethasone Dipropionate","moa":"||Glucocorticoid receptor","graph1":"Undisclosed","graph2":"Phase I","graph3":"Sofar Spa","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sofar Spa \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Sofar Spa \/ Inapplicable"}]

Find Clinical Drug Pipeline Developments & Deals for Sanasthmax

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          DARTNet Institute

                          Country arrow
                          EPSC
                          Not Confirmed

                          DARTNet Institute

                          Country arrow
                          EPSC
                          Not Confirmed

                          Lead Product(s) : Beclomethasone Dipropionate,Budesonide,Fluticasone Propionate,Mometasone Furoate,Ciclesodine,Azithromycin

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Study Phase : Phase IV

                          Sponsor : Penn State University | Icahn School of Medicine at Mount Sinai | University of Colorado, Denver | RAND Corporation | University of Washington | Rutgers University | University of North Carolina | Brigham and Women's Hospital | Reliant Medical Group | Kel

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          February 22, 2024

                          Lead Product(s) : Beclomethasone Dipropionate,Budesonide,Fluticasone Propionate,Mometasone Furoate,Ciclesodine,Azithromycin

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase IV

                          Sponsor : Penn State University | Icahn School of Medicine at Mount Sinai | University of Colorado, Denver | RAND Corporation | University of Washington | Rutgers University | University of North Carolina | Brigham and Women's Hospital | Reliant Medical Group | Kel

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Luforbec (formoterol) oral inhalation is used to control wheezing, shortness of breath, and chest tightness caused by chronic obstructive pulmonary disease.

                          Product Name : Luforbec

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          August 25, 2022

                          Lead Product(s) : Formoterol Fumarate,Beclomethasone Dipropionate

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          March 23, 2022

                          Lead Product(s) : Beclomethasone Dipropionate,Formoterol Fumarate

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          04

                          UPECLIN HC FM Botucatu Unesp

                          Country arrow
                          EPSC
                          Not Confirmed

                          UPECLIN HC FM Botucatu Unesp

                          Country arrow
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          June 24, 2021

                          Lead Product(s) : Beclomethasone Dipropionate,Formoterol Fumarate,Glycopyrronium Bromide

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Chiesi Group

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          05

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          May 06, 2021

                          Lead Product(s) : Beclomethasone Dipropionate,Formoterol Fumarate,Glycopyrronium Bromide

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase III

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          May 05, 2021

                          Lead Product(s) : Beclomethasone Dipropionate,Inapplicable

                          Therapeutic Area : Undisclosed

                          Highest Development Status : Phase I

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          07

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : European Commission has granted the marketing authorization for Trimbow inhalation powder delivered through NEXThaler (beclometasone dipropionate, formoterol fumarate dihydrate and glycopyrronium) for treatment of moderate to severe COPD.

                          Product Name : Trimbow

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          April 21, 2021

                          Lead Product(s) : Beclomethasone Dipropionate,Formoterol Fumarate,Glycopyrronium Bromide

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          08

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          March 26, 2021

                          Lead Product(s) : Azelastine Hydrochloride,Beclomethasone Dipropionate

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          09

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Under the terms of this agreement, RELIFE S.r.l shall register, promote, distribute and market Lipidor's calcipotriol based drug candidates for the treatment of psoriasis in EU, Turkey, UK, Switzerland, CIS, and Balkan countries.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          January 07, 2021

                          Lead Product(s) : Calcipotriol,Beclomethasone Dipropionate

                          Therapeutic Area : Dermatology

                          Highest Development Status : Phase III

                          Sponsor : Menarini

                          Deal Size : $83.1 million

                          Deal Type : Licensing Agreement

                          blank

                          10

                          EPSC
                          Not Confirmed
                          EPSC
                          Not Confirmed

                          Details : Trimbow is the first extrafine formulation fixed triple combination therapy in a single inhaler to be approved for use in appropriate asthma patients. This follows the 2017 approval of this therapeutic option for the treatment of appropriate moderate to ...

                          Product Name : Trimbow

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 02, 2021

                          Lead Product(s) : Beclomethasone Dipropionate,Formoterol Fumarate,Glycopyrronium Bromide

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Approved FDF

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank